Evidence map›Paper›PMID 22682899›Full record

ArticlePeptides2012

Nesfatin-1(30-59) but not the N- and C-terminal fragments, nesfatin-1(1-29) and nesfatin-1(60-82) injected intracerebroventricularly decreases dark phase food intake by increasing inter-meal intervals in mice.

Andreas Stengel, Miriam Goebel-Stengel, Lixin Wang, Ikuo Kato, Masatomo Mori, Yvette Taché

Abstract read
In one paragraph

Article in Peptides, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Exploration of Appetite Regulation in Yangtze Sturgeon (International journal of molecular sciences · 2025
    Article
  4. Article
  5. Article
  6. Premetazoan Origin of Neuropeptide Signaling.Molecular biology and evolution · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Current Understanding of the Role of Nesfatin-1.Journal of the Endocrine Society · 2018
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Andreas StengelCURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Digestive Diseases Division, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90073, USA.
Miriam Goebel-Stengel
Lixin Wang
Ikuo Kato
Masatomo Mori
Yvette Taché
University of California, Los Angeles · USCharité - Universitätsmedizin Berlin · DEGunma University · JPHokuriku University · JPVA Greater Los Angeles Healthcare System · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
CORTICOTROPIN-RELEASING FACTOR--BIOLOGICAL ACTIONR01DK033061 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TACHE, YVETTE FRANCE · 1986 to 2012
$2.5M
CORTICOTROPIN-RELEASING FACTOR-ACTION ON GI FUNCTIONR37DK033061 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TACHE, YVETTE FRANCE · 1995 to 2002
$869k
NIDDK NIH HHS DK-41301NIDDK NIH HHS P30 DK041301NIDDK NIH HHS R01 DK033061NIDDK NIH HHS R01 DK-33061NIDDK NIH HHS R37 DK033061
6 · The paper itself

Abstract

Nesfatin-1 is an 82 amino acid N-terminal fragment of nucleobindin2 that was consistently shown to reduce dark phase food intake upon brain injection in rodents. We recently reported that nesfatin-1(1-82) injected intracerebroventricularly (icv) reduces dark phase feeding in mice. Moreover, intraperitoneal injection of mid-fragment nesfatin-1 (nesfatin-1(30-59)) mimics the food intake-reducing effects of nesfatin-1(1-82), whereas N-terminal (nesfatin-1(1-29)) and C-terminal fragments (nesfatin-1(60-82)) did not. We therefore characterized the structure-activity relationship of nesfatin-1 injected icv to influence the dark phase meal pattern in mice. Mouse nesfatin-1(1-29), nesfatin-1(30-59), nesfatin-1(60-82) or vehicle was injected icv in freely fed C57Bl/6 mice immediately before the dark phase and food intake was monitored using an automated episodic feeding monitoring system. Nesfatin-1(30-59) (0.1, 0.3, 0.9 nmol/mouse) induced a dose-related reduction of 4-h food intake by 28%, 49% and 49% respectively resulting in a 23% decreased cumulative 24-h food intake compared to vehicle at the 0.3 nmol/mouse dose (p<0.05). The peak reduction occurred during the 3rd (-96%) and 4th hour (-91%) post injection and was associated with a reduced meal frequency (0-4h: -47%) and prolonged inter-meal intervals (3.1-times) compared to vehicle (p<0.05), whereas meal size was not altered. In contrast, neither nesfatin-1(1-29) nor nesfatin-1(60-82) reduced dark phase food intake at equimolar doses although nesfatin-1(60-82) prolonged inter-meal intervals (1.7-times, p<0.05). Nesfatin-1(30-59) is the active core of nesfatin-1(1-82) to induce satiety indicated by a reduced meal number during the first 4h post injection. The delayed onset may be indicative of time required to modulate other hypothalamic and medullary networks regulating nocturnal feeding as established for nesfatin-1.

Indexed as

AnimalsBrainCalcium-Binding ProteinsDNA-Binding ProteinsEatingFeeding BehaviorInjections, IntraventricularMaleMiceMice, Inbred C57BLNerve Tissue ProteinsNucleobindinsPeptide FragmentsPhotoperiodStructure-Activity RelationshipCalcium-Binding ProteinsDNA-Binding ProteinsNerve Tissue ProteinsNucb1 protein, mouseNucleobindinsPeptide Fragments

Identifiers

PMID22682899
PMCPMC3372867
OpenAlexW2030149722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.